
|Videos|January 24, 2022
Assessing the Burden of Atherosclerotic Cardiovascular Disease in the US
Norman Lepor, MD, a cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), discusses the burden of ASCVD in the country today.
Advertisement
Pharmacy Times interviewed Norman Lepor, MD, a Los Angeles-based cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), on the burden of atherosclerotic cardiovascular disease (ASCVD) and low-density lipoprotein cholesterol management.
During the interview, Lepor discussed the burden of ASCVD in the country today.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Grants Priority Review to Gedatolisib for HR+, HER2-Negative Advanced Breast Cancer
2
Circulating Tumor Cells May Guide Use of Tarlatamab in Small Cell Lung Cancer
3
Pharmacists Can Implement Test-and-Treat Services in Their Practice Settings
4
Unique Pharmacy Technician Career Ladder Meets the Needs of a Growing Profession
5



















































































































































































































